Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPI | P34949 | 1/20 | 0.41 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.40 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.38 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.35 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.35 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1561362 | 0.86 | LPAR1 (0.51) | MPIF10LPAR1CXCR5 | |
| SCHEMBL18874328 | 0.80 | CXCR5 (0.47) | CXCR5TRPV1 | |
| SCHEMBL18874410 | 0.80 | LPAR1 (0.55) | LPAR1CXCR5TRPV1 | |
| SCHEMBL18874194 | 0.80 | LPAR1 (0.60) | MPIF10LPAR1GRM4 | |
| SCHEMBL1560554 | 0.73 | LPAR1 (0.60) | MPIF10LPAR1CXCR5TRPV1 | |
| SCHEMBL18874315 | 0.72 | LMNA (0.42) | LPAR1CXCR5 | |
| SCHEMBL1561391 | 0.70 | LPAR1 (0.56) | F10LPAR1CXCR5 | |
| SCHEMBL18874199 | 0.67 | LPAR1 (0.57) | LPAR1CXCR5 | |
| SCHEMBL18874159 | 0.67 | LPAR1 (0.57) | LPAR1CXCR5 | |
| SCHEMBL6066448 | 0.67 | F10 (0.56) | F10TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303270-B1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2017-05-17 | — | — | EP | disclosed |